• Something wrong with this record ?

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

K. Horska, J. Ruda-Kucerova, E. Drazanova, M. Karpisek, R. Demlova, T. Kasparek, H. Kotolova,

. 2017 ; 123 (-) : 148-158.

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18024958

Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024958
003      
CZ-PrNML
005      
20180717093804.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.neuropharm.2017.06.003 $2 doi
035    __
$a (PubMed)28595931
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Horska, Katerina $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
245    10
$a Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats / $c K. Horska, J. Ruda-Kucerova, E. Drazanova, M. Karpisek, R. Demlova, T. Kasparek, H. Kotolova,
520    9_
$a Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.
650    _2
$a aplikace orální $7 D000284
650    _2
$a zvířata $7 D000818
650    _2
$a antipsychotika $x škodlivé účinky $x farmakologie $7 D014150
650    _2
$a aripiprazol $x škodlivé účinky $x farmakologie $7 D000068180
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a cytokiny $x krev $7 D016207
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ghrelin $x krev $7 D054439
650    _2
$a glukagonu podobný peptid 1 $x krev $7 D052216
650    _2
$a leptin $x krev $7 D020738
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolický syndrom $x krev $x chemicky indukované $7 D024821
650    _2
$a poly I-C $7 D011070
650    _2
$a náhodné rozdělení $7 D011897
650    _2
$a potkani Wistar $7 D017208
650    _2
$a schizofrenie $x krev $x farmakoterapie $7 D012559
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: jkucer@med.muni.cz.
700    1_
$a Drazanova, Eva $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Scientific Instruments, ASCR, Brno, Czech Republic.
700    1_
$a Karpisek, Michal $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic; R&D Department, Biovendor - Laboratorni Medicina, Brno, Czech Republic.
700    1_
$a Demlova, Regina $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kasparek, Tomas $u Department of Psychiatry, University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Kotolova, Hana $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
773    0_
$w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 123, č. - (2017), s. 148-158
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28595931 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180717094103 $b ABA008
999    __
$a ok $b bmc $g 1317089 $s 1021879
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 123 $c - $d 148-158 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options